Log in to your Inderes Free account to see all free content on this page.
Immunovia
0.495
SEK
+0.61 %
IMMNOV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+0.61%
-9.34%
-23.85%
-23.26%
-37.72%
-47%
-98.39%
-99.38%
-96.38%
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Read moreMarket cap
84.01M SEK
Turnover
1.99M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
25.2.
2025
Annual report '24
14.5.
2025
General meeting '25
14.5.
2025
Interim report Q1'25
ShowingAll content types
Immunovia AB: The exercise period for warrants of series TO 2 beings today
Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio